Strategic area of application
Human Medicine
Application market
Infectiology - Parasitology - Others
Activities
Therapeutics, Pharma or Biotech
Technologies
Antibodies - Protein - Peptide
Fab’entech is a privately owned biopharmaceutical SME developing immunotherapies to address situations of emergency. Based on its horse F(ab’)2 platform, a fully-derisked technology in-licensed from Sanofi Pasteur, Fab’entech aims to provide therapeutic solutions in the fields of biodefense, drug intoxication and infectious disease.
Looking for funding: Yes
Private funding obtained: Fab'entech has obtained almost 7 M€ of private funding over the last 8 years, including 1.7 M€ from private investors progressively between 2009 and 2011, and 5 M€ from investment funds in 2014.
Public funding obtained: Fab'entech has obtained almost 11 M€ of public funding over the last 8 years, thanks to grant programs provided by Grand Lyon, Lyonbiopôle, BPI France, DGCIS, the European Commission, etc.
Strategic area of application
Human Medicine
Application market
Infectiology - Parasitology - Others
Activities
Therapeutics, Pharma or Biotech
Technologies
Antibodies - Protein - Peptide